Home > Boards > US OTC > Biotechs > InNexus Biotechnology Inc. (IXSBF)
Followed By 0
Posts 154
Boards Moderated 0
Alias Born 04/03/2009

Thursday, December 10, 2009 12:31:48 PM

Re: None

Post# of 17
InNexus And XERIS Announce Research Collaboration
9:00 AM ET 12/10/09 | BusinessWire
InNexus Biotechnology Inc. (TSX.V:IXS) (www.ixsbio.com) and XERIS Pharmaceuticals, Inc. (www.xerispharma.com) announced today a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus' Dynamic Cross Linking (DXL(TM)) antibodies using XERIS' proprietary formulation-injection technologies.

"We see a need for an improved delivery system for antibodies that enables self injection of these important therapeutic agents, by patients at home," said John Kinzell, CEO of XERIS. "Our delivery system addresses a number of major issues related to storing and administering antibodies and is suitable for and could add value in both chronic and acute therapies."

Jeff Morhet, CEO of InNexus said, "We continue to demonstrate applicability of our DXL technology to a variety of disease targets and we are excited to work with XERIS to identify DXL antibodies which are suitable for subcutaneous delivery to patients using XERIS formulation-injection technology. Antibodies are the leading choice of pharmaceutical companies for drug development and we will continue to position InNexus and our technology to take advantage or the industry's growth. This collaboration is novel and showcases two dynamic technologies."

InNexus also announced that it will be hosting a shareholder teleconference on December 10, 2009 at 4:15 PM Eastern Time to discuss outlook and plans for InNexus in the upcoming year. Participants can dial 1-877-551-8166 to participate in the call.

InNexus Resources

-- AACR 2008 Scientific Poster on DXL625(TM)

-- DXL(TM) Pipeline & Programs

-- Stock Quick Check

-- Scientific Advisory Board

-- Leadership Team

About InNexus Biotechnology

InNexus Biotechnology Inc. is a public biotechnology company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency and safety of existing antibody products, thus expanding their usefulness, enabling new disease applications and opening new markets. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus. Headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic, InNexus has its own development facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. InNexus Biotechnology Inc. is listed on the TSX Venture Exchange (TSX.V:IXS). To learn more about InNexus, please visit www.ixsbio.com.

XERIS is an early-stage, specialty biopharmaceutical company developing patient-friendly injectables to treat endocrine and metabolic diseases. The company's formulation-injection technologies allow the subcutaneous delivery of highly concentrated, semi-solid formulations of all drug classes, including small molecules, peptides, proteins, antibodies, and nucleotide-based therapeutics. XERIS' proprietary delivery system offers distinct advantages over existing needle and "needle-free" delivery approaches, including ease of use, less discomfort, room-temperature stability and broad dosing flexibility. To learn more about XERIS, please visit www.xerispharma.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.

SOURCE: InNexus Biotechnology Inc.

View dataInNexus Biotechnology Inc.
Jeff Morhet, Chairman & Chief Executive Officer
XERIS Pharmaceuticals, Inc.
John Kinzell, President & CEO

InNexus Biotechnology Inc. Jeff Morhet, Chairman & Chief Executive Officer 1-480-862-7500 http://www.ixsbio.com or XERIS Pharmaceuticals, Inc. John Kinzell, President & CEO 1-415-250-8763 http://www.xerispharma.com
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y